New Haven, CTNCT06411210Now EnrollingIRB Ready

Diabetes type1 Clinical Trial in New Haven, CT

Access cutting-edge diabetes type1 treatment through this phase 2 clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access diabetes type1 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related diabetes type1 treatment provided free

Apply for This New Haven Location

Check if you qualify for this diabetes type1 clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Diabetes type1 Study in New Haven

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity)
Clinical diagnosis of T1D
Diabetes duration diagnosed ≥ 12 months ago
HbA1c ≤10% at screening and within the past 90 days
Stable reported insulin dosing in the past 90 days (within 15%)
Stable reported BMI in the past 90 days (within 5%)
Ability to provide written informed consent before any trial-related activities
Use of real-time continuous glucose monitoring and planned continued use
Females and males of childbearing potential willing to use highly effective methods of contraception for at least 1 month prior to randomization and agreement to use such a method during study participation and for 2 months after the last dose of study medication administration: Combined estrogen-progestogen contraception including: oral, intravaginal, transdermal (patch), Progestogen-only contraception: oral, injectable or implantable, Placement of an intrauterine device or intrauterine system, Bilateral tubal occlusion (fallopian tubes are blocked), Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate), or Complete sexual abstinence from male-female sex)
Stated willingness to comply with all study procedures, medication regimen, and availability for the duration of the study
Participants cannot be randomized if any laboratory safety parameter at screening is outside the below extended laboratory ranges. For randomization, participants should have
Creatinine \<1.0mg
Triglycerides (\<400 mg/dl)
ALT \<3.5 times the upper normal limit (UNL)

Exclusion Criteria

Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months.
Insulin dosing \<0.5 units/kg/day
Current psychiatric conditions impacting weight, including known eating disorders
Contraindications to study medications, including:
Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis
Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2
Known or suspected allergy to semaglutide, excipients, or related products.
Use of lipid lowering medications other than statins and omega-3 products
Previous randomization in this trial. Participants who enrolled but did not randomize can be re-screened. Potential reasons for enrolment without randomization include scheduling conflicts for the baseline studies, or for females, not yet meeting the highly effective methods of contraception criteria.
Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures
Diabetic ketoacidosis in the past 6 months
Not meeting MRI safety criteria or claustrophobia preventing participation in the MRI
Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation.
Treatment with another investigational drug or other intervention within the past 1 month
Subjects with a PHQ-9 score \>15 or those found to have a lifetime history of suicide attempts, or suicidal ideation within the past 3 months on the C-SSRS
Corn allergy
Subjects with severe hypoglycemia requiring hospitalization in the past 3 months
Clinically significant gastroparesis

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT06411210) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diabetes type1 Treatment Options in New Haven, CT

If you're searching for diabetes type1 treatment options in New Haven, CT, this clinical trial (NCT06411210) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced diabetes type1 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diabetes type1 clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in New Haven, CT

See all pulmonary embolism clinical trials recruiting in New Haven — not just this study.

Browse Pulmonary Embolism Trials in New Haven →

Browse More Trials by Condition

Pulmonary Embolism TrialsEssential Tremor TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT